Incretin therapies expand role in obesity and metabolic health

Medical experts gathered in Rome for the 2026 workshop on incretins and metabolic health to discuss the evolving landscape of obesity and weight management treatments. Following the success of semaglutide and tirzepatide, the pharmaceutical pipeline is shifting toward new molecules, oral formulations, and micro-dosing options.

Research indicates that incretin-mimetic therapies offer benefits beyond weight loss, including protection for the heart, liver, and blood vessels. There is also emerging evidence regarding their potential role in neuroprotection against neurodegenerative diseases like Alzheimer’s and dementia, as well as positive impacts on female reproductive health.

The symposium highlighted the transition from injectable treatments to oral pills, noting recent FDA approvals for oral GLP-1 semaglutide and orforglipron. Experts emphasized the importance of using these therapies early as primary prevention to manage metabolic health and reduce cardiovascular mortality.